TESTING COMPLIANCE OF DRUG TAKING-A SIMPLE BED SIDE METHOD

Similar documents
Official Letter from the DOH

A. TRIAL IDENTIFICATION

PHAR 7633 Chapter 23 Pharmacodynamic Models and Physiologically Based Pharmacokinetic Models

Dr. M.Mothilal Assistant professor

Institute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1

INTRODUCTION TO CLINICAL PHARMACY

ORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT. Dr Philippe CASSIER Centre Léon Bérard, Lyon

INTRODUCTION TO PHARMACOLOGY

Antidotum Thallii-Heyl

Public Assessment Report Scientific discussion. Acetylsalicylsyra ABECE (acetylsalicylic acid) Asp no:

Standards for Safety Assessments of Food Additives produced Using Genetically Modified Microorganisms

Pharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal

CLINICAL STUDY REPORT SYNOPSIS

Technical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997

SAMPLE PAPER PHARMACY TECHNICIAN SECOND YEAR PART II PAPER 1

Approval Review of Generic Drugs. Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D.

BIOEQUIVALENCE TRIAL INFORMATION FORM (Medicines and Allied Substances Act [No. 3] of 2013 Part V Section 39)

KEY WORDS Pharmacokinetics, modeler, hands-on, safety, practical class, clinical training.

Research Article. Concomitant therapy in clinical trials of drugs: Its role, problems and approaches to its consideration

Approaches to Development of Analytical Method for Combination Products Containing Fluconazole

ESETT PHARMACOKINETIC PHARMACODYNAMIC (PK/PD) STUDY TRAINING

Design and Dosage Form. Dr. Deny Susanti

Introduction to Pharmacology. Prepared by: Shaikh Abusufyan, M. Pharm (Pharmacology)

S9 Nonclinical Evaluation for Anticancer Pharmaceuticals

Clinically Relevant Specifications (CRS): A Regulatory Perspective

Learning about Clinical Trials

FREQUENTLY ASKED QUESTIONS

Public Assessment Report Scientific discussion. Naproxen ABECE (naproxen) Asp no:

A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma

NUVISAN GROUP. Our Philosophy

Introduction PART. 1 Why Technicians Need to Study Pharmacology and Therapeutics. 2 Pharmacokinetics

CHALLENGES AND OPPORTUNITIES ON FORMULATION AND DEVELOPMENT OF FIXED DOSE COMBINATIONS: UNIGEL, A TECHNOLOGICAL PLATFORM

Toxic Effects of Aluminium

Clinical Study Synopsis

March 23, Francis S. Collins, M.D., Ph.D Director, National Institutes of Health 9000 Rockville Pike Bethesda, Maryland 20892

Copper: Essential for Human Health

The genetic material is arranged differently in the cells of bacteria compared with animal and plant cells.

Effect of Residual Feed Intake, Gender, and Breed Composition on Plasma Urea Nitrogen Concentration in an Angus-Brahman Multibreed Herd

Comparison of plain egg medium with Lowenstein- Jensen medium in the isolation of M. tuberculosis from sputum.

International Journal of Health Sciences and Research ISSN:

Fentanyl (Human) ELISA Kit

Acceptance of Foreign Clinical Data A U.S. Perspective

First UNGAP meeting Food-Drug Interactions Regulatory Aspects

CHAPTER 2 CONVERTING ANALOG SIGNAL TO DIGITAL BY INTRODUCING THRESHOLD ENABLES VISUAL READOUT FOR A CYSTATIN C QUANTIFICATION ASSAY

From Bench to Bedside. Russ H. Read June 23, 2014

Bevyxxa (betrixaban) NEW PRODUCT SLIDESHOW

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2

DOACs: When and how to measure their anticoagulant effect

Gaucher Clinic 2007: Clinical trials

The views and opinions expressed in the following PowerPoint slides are

Bioavailability and Bioequivalence Studies

Trend in diagnostic biochip. Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital

ESETT PHARMACOKINETIC PHARMACODYNAMIC (PK/PD) STUDY. Lisa Coles, MS, PhD University of Minnesota

Pharmacokinetics of Cloxacillin in Humans

Biopharmaceutics. Lecture :1. Module Introduction and Introduction to Biopharmaceutics

Doctor of Pharmacy Course Descriptions

EAHP STATEMENT ON THE NEED FOR BARCODING OF THE SINGLE DOSE ADMINISTERED IN HOSPITALS

Oral Delivery of Drugs

I. Purpose. II. Definitions. Last Approval Date

OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE

YOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING

MAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL SAFETY STUDIES FOR THE CONDUCT OF HUMAN CLINICAL TRIALS FOR PHARMACEUTICALS M3(R1)

FIRST YEAR PHARM. D. Know about the theory and their application in pharmacy PDM107 Remedial Mathematics

Research Article Pharmaceutical Sciences

Office for Human Subject Protection. University of Rochester

Variables and data types

The Journal of General Physiology

Rules of Human Experimentation

Public Assessment Report Scientific discussion. Desogestrel Orifarm (desogestrel) SE/H/888/01/DC

Outline 4/25/2013. Titanium Dioxide Pigment and Nano Grades. Disclaimer

RE: CPMT Pharmacokinetic Analyses of Fixed-Dose Drug Combinations for Pediatric Tuberculosis

Guidance for Industry

The Role of a Clinical Statistician in Drug Development By: Jackie Reisner

Forecast diagnostics for antimicrobial resistance (AMR)

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

Organic Pharmaceutical Chemistry: Prodrugs

á232ñ ELEMENTAL IMPURITIES LIMITS

BIOPHARMACEUTICS CLASSIFICATION SYSTEM-BASED BIOWAIVERS - M9

GUIDELINES FOR CONDUCTING CLINICAL TRIALS.

A GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE

Introduction to Drug Design and Discovery

January (San Francisco, CA) January 8, 2018

M&S in early development (to support FTiM)

Nanomedicine for Improved Efficacy of Tuberculosis Drugs Pharmacokinetic importance

TANZANIA FOOD AND DRUGS AUTHORITY

Fig. 4. A two-compartment pharmacokinetic model.

Urodynamic Measurement System

Bureau of Laboratory Quality Standards

Iron metabolism. And. Anemia in chronic kidney disease

Last Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4

IV3-105E. High Sensitivity CRP (hscrp) ELISA Kit. Definitions LOT REF. English. For in-vitro diagnostic use only IVD. Instructions for use

Economic evaluation of zinc and copper use in treating acute diarrhea in children: a randomized controlled trial Patel A B, Dhande L A, Rawat M S

Voriconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version May 2012

IRON ABSORPTION IN DOGS DURING ANEMIA DUE TO ACETYLPHENYLHYDRAZINE

The connection between genes, proteins and metabolism CAMPBELL BIOLOGY

In silico Prediction of Bioavailability of Pharmaceutical Formulations Using Population Pharmacokinetic Model Simulation

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL GENERAL FORMS AND GUIDELINES MYELOMA FORMS CHAPTER 16D REVISED: SEPTEMBER 2016

Review Article. Regulatory Consideration for BA/BE Studies in Indian Scenario.

Urea Assay Kit. Catalog Number KA assays Version: 02. Intended for research use only.

Transcription:

TESTING COMPLIANCE OF DRUG TAKING-A SIMPLE BED SIDE METHOD N. Thilothammal P.V. Krishnamurthy K. Banu S. Gandhimathy ABSTRACT Assessment of compliance in drug taking is a problem in a crowded Outpatient Department. Using riboflavin as a urinary marker is a simple and rational method. Identifying riboflavin in the urine by fluorescence on exposure to ultraviolet (UV) rays or torch light is being used in medical practice but not extensively. In this study, the validity and reliability of these methods were assessed. The sensitivity and specificity of this test by UV method was 86% and 82% for Reader I (medical person) and 82% and 94% for Reader II (paramedical person). For Reader I, the accuracy of reading by UV lamp was the same as torch light (85%) whereas for Reader II the accuracy was better with UV lamp (87%) than with torch (79%). In reading the fluorescence by UV lamp the crude agreement between the 2 readers was 82% and chance corrected agreement was 64%. UV lamp method appears to be a reliable way of assessing compliance both by medical and paramedical persons whereas torch method appears to be more reliable when used by a medical person than by a paramedical person. Key words: Compliance, Riboflavin, UV lamp method. The major problem in chronic drug therapy whether it is the treatment of epilepsy or tuberculosis is poor compliance. Most often compliance is often verified in a busy Outpatient Department from the parental history. Pill counting is not possible as many patients do not bring the drug container because either they are so illiterate or they do not want to disclose their irregularity in drug intake. In the management of epilepsy, compliance needs to be verified especially in situations where adjustment of drug dosage is required. History alone from an ignorant illiterate parent may not give the true position. Estimation of drug level would be more accurate but it is expensive and time consuming and is not carried out in all the hospitals in our country. Hence, it is important to have a simple, inexpensive and less time consuming bed side test to assess compliance. If a pharmacologically inert substance, which can be readily detected in an accessible body fluid, is added to the tablet under investigation, then screening of the body fluid for the inert substance would provide a technically simple test. Riboflavin, on oral administration, is absorbed in the upper gastrointestinal tract, bound to plasma protein From the Clinical Epidemiology Unit, Institute of Child Health and Hospital for Children, Madras and Tuberculosis Research Centre, Indian Council of Medical Research, Madras 600 004. Reprint requests: Dr. N. Thilothammal, No. 16, First Main Road, C.I.T. Colony, Myalopore, Madras 600 004. Received for publication: November 9,1993; Accepted: July 13,1994

THILOTHAMMAL ET AL. in the blood and excreted in the urine as the free vitamin. This may be detected qualitatively in the urine by its fluorescence on exposure to ultraviolet light. It does not cause adverse pharmacological effects(l-3). To assess compliance, in this study we utilized riboflavin tablets with or without active medication and screened the urine of these patients for fluorescence under ultraviolet (UV) lamp and torch light. The study had the following objectives : (i) To assess the validity of this test in identifying children who have taken ribflavin; (ii) To find out the inter observer variation in reading the fluorescence effect; and (iii) To determine the minimal dose of riboflavin required to produce fluorescence in the urine sample 12 to 14 hours after ingestion. Subjects and Methods Two methods were used to assess the presence of fluorescence in urine. 1. UV lamp method(4): Fluorescence was tested by exposing the urine to ultra violet light using a "ADCO cabinet type model UV-BT long wave length lamp". Urine was placed in a wide bottomed beaker with water in a similar beaker as control. When a milky white fluorescence was observed, the test was said to be positive, otherwise it was considered negative. 2. Another documented method is examining urine, in a universal blood tube, for fluorescence by a narrow beam of light emanating from a pen torch against a matt black background (5). Though this is a coarse method, its advantage is that only specimens showing TESTING DRUG COMPLIANCE high levels of riboflavin will be positive. Forty four (44) children in the age group 4-12 years were recruited and randomized into two groups. One group was advised to take riboflavin tablet at 9 PM and to attend hospital at 9 AM the next day. The other group was advised not to take any tablet and to attend the hospital the next day. Five children belonging to the second group did not attend the hospital the next day. The volunteers were children attending seizure clinic and their siblings. No dietary restriction was imposed on the children but they were asked to avoid all medication from 24 hours prior to taking the riboflavin tablet till the completion of the test. Those on anti epileptic drugs were advised to continue the drugs. The urine samples from children who consumed riboflavin and from those who did not consume riboflavin were numbered and arranged in a random sequence by a third investigator. The coding of the sequence was kept in a file. A medical and a paramedical person were then asked to screen the urine by both methods, independently and give their results. They were totally blind to the knowledge of riboflavin consumption by children. Their results were tabulated. In order to find out the minimal dosage of riboflavin required to produce fluorescence in urine, we recruited 75 children separately in the age group 4-12 years. These also included patients attending the seizure clinic and their siblings. These children were divided into 3 groups of 25 children each. The first group was instructed to take 10 mg of riboflavin at 9PM, the second group to take 20 mg of riboflavin at 9 PM and 296

INDIAN PEDIATRICS the third group to take 30mg of riboflavin at 9 PM. They were all asked to report at 9 AM the next day. Samples of urine were collected at 9 AM, 10 AM and 11 AM for all 75 children. All the samples were tested for fluorescence by a medical officer using UV lamp method. Results Data from 39 volunteers were used for calculating test characteristics like sensitivity, specificity, positive predictive value and negative predictive value for both UV method and torch method. Inter-observer variation was calculated by kappa statistics. Data from 75 different volunteers were used to calculate the proportion of patients whose urine was positive for fluorescence test, at variable intervals after ingestion of riboflavin. Proportion of patients who had positive tests in three groups consuming 10 mg, 20 mg and 30 mg, respectively were calculated. When UV lamp method was used, sensitivity of the test was 86% for Reader I (medical officer) and 82% for Reader II (paramedial person). The specificity of this test was 82%'and 94% and the positive predictive values were 86% and 95% for Readers I and II, respectively. When torch method was used, sensitivity of the test was 86% for Reader I and 68% for Reader II. The specificity of this test was 82% and 94% and the positive predictive values were 86% and 94% for Readers I and II, respectively. For Reader I, accuracy of reading by UV lamp was the same as torch light (85%), whereas for Reader II, the accuracy was better with UV lamp (87%) than with torch (79%). VOLUME 32-MARCH 1995 The presence of riboflavin in the urine was identified by Reader I, by both methods, in 18 out of 22 patients given riboflavin. Reader II identified riboflavin by both methods in 15 samples. The absence of fluorescence in the urine was identified by Reader I, by both methods, in 13 out of 17 patients who were not given riboflavin. Reader II identified absence of fluorescence in the urine, by both methods in 15 out of 17 samples (Table I). When test results of UV lamp method were compared between Readers I and II, 32 observations agreed out of 39. The crude agreement was 82% (Table II) and chance corrected agreement (Kappa) was 64%. When test results of torch method were compared between Readers I and II, 33 observations agreed out of 39. The crude agreement was 85% (Table III) and chance corrected agreement (Kappa) was 70%. All 75 patients showed fluorescence upto 13 hours after consumption of riboflavin. For those who received 30 mg, 88% showed positive test even at 14 hours whereas among children who received 20 mg, only 52% showed positive test at the end of 14 hours. Of children who received 10 mg, only 32% showed fluorescence at the end of 14 hours. Discussion Assessment of compliance using riboflavin as a urinary marker is a technically simple and rational method. It is quick, non-invasive and can be carried out for any drug. This test could be done either in the Out Patient Department or at the bedside, both by a medical and by a non medical person(4-6). In our study, the accuracy of UV 297

lamp method for the two readers was 85% and 87% and for torch method it was 85% and 79%, respectively. The inter-observer agreement as assessed by Kappa statistic was moderate. The study by Jones also revealed the accuracy of torch method to be 92%(5). In the group that ingested 30 mg of riboflavin, a high proportion (88%) showed positive urine results at 14 hours whereas in the group that received 10 mg, a very low proportion (32%) showed fluorescence at the end of 14 hours. The higher the amount of riboflavin ingested, the greater is the proportion detected as riboflavin positive. Similarly riboflavin can be detected in the urine for a longer period when more is ingested. A minimal dose of 10 mg is adequate to detect riboflavin in the urine upto 13 hours in all patients. 298

INDIAN PEDIATRICS VOLUME 32-MARCH 1995 Similar observations have been made by other authors(7). A limitation to this technique is that occasional false positive and false negative results can occur. False positive readings could occur due to increased ingestion of foods containing riboflavin. False negative readings could be due to fast urinary excretion of the vitamin. The presence of phosphates and cells in the urine can impair its translucency and make reading difficult. Addition of acetic acid clears phosphates and cells usually settle down if left for half an hour(5). It is possible for the patient who consciously sets out to mislead the clinician and who knows about the method, to succeed by taking a tablet or two before he is seen, but this is not likely to be a common phenomenon. Probably, factors at a much less conscious level are responsible for irregular medication, and perhaps this method will allow some of these factors to be investigated(5). In conclusion, we recommend that UV lamp method be adapted to assess compliance of drug intake in any situa- tion where long term therapy is required. Torch method appears to be less accurate then UV method. REFERENCES 1. Jusko WJ, Levy G and Yaffe SJ. Effect of age on intestinal absorption of riboflavin in humans. J Pharm Sci 1970,59: 487-490. 2. Jusko WJ, Levy G. Absorption, metabolism, and excretion of riboflavin- 5-phosphate in man. J Pharm Sci 1967, 56: 58-62. 3. Rivlin RS. Riboflavin metabolism. New Eng J Med 1970, 283: 463-472. 4. Silberstein RM, Blackman S. A method to evaluate whether patients take pre scribed medication. Clin Pediatr 1966, 5: 239-240. 5. Jones IH. Riboflavine as an indicator of drug taking behavior. Med J Aust 1967/4: 202-204. 6. Jay MS, DuRant RH, Shoffitt T, Linder CW, Litt IF. Effect of peer counselors on adolescent compliance in use or oral contraceptives. Pediatrics 1984, 73:126-130. 7. Levy G, Jusko WJ. Factors affecting the absorption of riboflavin in man. J Pharm Sci 1966, 55: 285-289. 299